Loading
A phase 3 trial of Elranatamab, Lenalidomide in multiple myeloma, run by Pfizer, active and no longer recruiting.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant is a phase 3 interventional study registered as NCT05317416 by Pfizer, with 854 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2027-08-04. Interventions recorded: Elranatamab, Lenalidomide, Lenalidomide, Elranatamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Elranatamab, Pfizer (incl. Seagen), T-cell engagers (bispecific), Multiple myeloma.
Shares Elranatamab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Pfizer (incl. Seagen).
Shares Elranatamab, PROTACs & molecular glues (targeted protein degradation), Pfizer (incl. Seagen), T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Elranatamab, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific), Multiple myeloma.
Shares Elranatamab, PROTACs & molecular glues (targeted protein degradation), Pfizer (incl. Seagen), T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/